Retour

Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing

News News

Thursday, Century Therapeutics (NASDAQ:IPSC) unveiled plans to expand clinical development for its lead program, CNTY-101, a CD19-targeting iNK cell therapy, into additional autoimmune disease indications.  CNTY-101 is currently being evaluated in a clinical trial in B-cell malignancies (ELiPSE-1) as well as a planned trial in systemic lupus erythematosus (SLE) (CALiPSO-1), which is on track to be initiated in the first half of 2024.  Century Therapeutics plans to pursue additional autoimmune disease indication regulatory filings in 2024.  The company announced a $60 million private placement to support Century Therapeutics’ increased R&D activities in autoimmune diseases.  Century will issue approximately 15.87 million shares at $3.78. The company estimates that its cash, cash equivalents, and investments will support operations into 2026. Concurrently, Century announced pipeline and ...Full story available on Benzinga.com

Benzinga • 11/04/2024 à 22:24:12
Century Therapeutics, Inc. Common Stock
Address: 25 N 38TH STREET, 11TH FLOOR
Postal Code: 19104
City: PHILADELPHIA
State: PA
Phone Number: 215-981-4000
Website: https://www.centurytx.com
Status: Active
Company Info

Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.

List Date2021-06-18
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001850119
Composite figiBBG00PM8N5W0
Share Class figiBBG00PM8N5Y8
Market Cap259,312,284 USD
SIC Code2836
SIC DescriptionBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Total Employees165
Share Class Shares Outstanding82850000
Weighted Shares Outstanding82847375
Round Lot100
Updated date2024-05-12
Stats
Last 5 days
15-05
14-05
13-05
10-05
9-05
Last
3.1
3.14
3.005
3.154
3.174
Variance
-1.59%
4.49%
-5.5%
-0.66%
3.39%
Open
3.15
3.005
3.18
3.175
3.07
Highest
3.217
3.209
3.304
3.513
3.214
Lowest
3.215
3.205
3.221
3.415
3.207
History
PeriodVarhighestlowest
1 week
0.98%
3.214
3.205
1 month
-26.82%
4.244
3.035
3 month
-33.76%
4.88
3.035
6 month
140.31%
1.37
1.29
1 year
-4.32%
3.315
1.28
3 year
-84.1%
22.83
1.28
5 year
-84.1%
22.83
1.28
10 year
-84.1%
22.83
1.28
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-09 2023-11-09 UNPUB
Assets 456,228,000 417,159,000 397,551,000 UNPUB
Current Assets 255,934,000 161,280,000 173,703,000 UNPUB
Current Liabilities 27,684,000 19,161,000 20,435,000 UNPUB
Equity 277,175,000 247,571,000 219,230,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 277,175,000 247,571,000 219,230,000 UNPUB
Liabilities 179,053,000 169,588,000 178,321,000 UNPUB
Liabilities And Equity 456,228,000 417,159,000 397,551,000 UNPUB
Noncurrent Assets 200,294,000 255,879,000 223,848,000 UNPUB
Noncurrent Liabilities 151,369,000 150,427,000 157,886,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-09 2023-11-09 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 2,567,000 -22,393,000 -9,132,000 UNPUB
Net Cash Flow, Continuing 2,567,000 -22,393,000 -9,132,000 UNPUB
Net Cash Flow From Financing Activities 448,000 -10,117,000 300,000 UNPUB
Net Cash Flow From Financing Activities, Continuing 448,000 -10,117,000 300,000 UNPUB
Net Cash Flow From Investing Activities 31,338,000 6,974,000 4,217,000 UNPUB
Net Cash Flow From Investing Activities, Continuing 31,338,000 6,974,000 4,217,000 UNPUB
Net Cash Flow From Operating Activities -29,219,000 -19,250,000 -13,649,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -29,219,000 -19,250,000 -13,649,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-09 2023-11-09 UNPUB
Comprehensive Income/Loss -30,077,000 -33,223,000 -32,817,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -30,077,000 -33,223,000 -32,817,000 UNPUB
Other Comprehensive Income/Loss 1,187,000 -33,223,000 -32,817,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-09 2023-11-09 UNPUB
Basic Earnings Per Share -1 -1 -1 UNPUB
Benefits Costs and Expenses 31,776,000 32,440,000 32,276,000 UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 31,776,000 32,440,000 32,276,000 UNPUB
Diluted Earnings Per Share -1 -1 -1 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -31,264,000 -33,291,000 -32,720,000 UNPUB
Income/Loss From Continuing Operations Before Tax -30,056,000 -32,341,000 -32,128,000 UNPUB
Income Tax Expense/Benefit 1,208,000 950,000 592,000 UNPUB
Interest Expense, Operating 404,000 136,000 0 UNPUB
Net Income/Loss -31,264,000 -33,291,000 -32,720,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -31,264,000 -33,291,000 -32,720,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -31,264,000 -33,291,000 -32,720,000 UNPUB
Operating Expenses 33,801,000 35,176,000 35,774,000 UNPUB
Operating Income/Loss -32,081,000 -35,077,000 -35,626,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 1,720,000 99,000 148,000 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-16 2022-08-11 2022-11-10 2023-03-16
Assets 550,308,000 532,584,000 511,751,000 486,544,000
Current Assets 365,262,000 383,793,000 361,641,000 319,721,000
Current Liabilities 21,976,000 21,569,000 26,907,000 29,817,000
Equity 386,664,000 357,952,000 330,205,000 302,738,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 386,664,000 357,952,000 330,205,000 302,738,000
Liabilities 163,644,000 174,632,000 181,546,000 183,806,000
Liabilities And Equity 550,308,000 532,584,000 511,751,000 486,544,000
Noncurrent Assets 185,046,000 148,791,000 150,110,000 166,823,000
Noncurrent Liabilities 0 0 154,639,000 153,989,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-16 2022-08-11 2022-11-10 2023-03-16
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 69,594,000 -12,990,000 -1,437,000 28,082,000
Net Cash Flow, Continuing 69,594,000 -12,990,000 -1,437,000 28,082,000
Net Cash Flow From Financing Activities 26,878,000 47,000 138,000 27,158,000
Net Cash Flow From Financing Activities, Continuing 26,878,000 47,000 138,000 27,158,000
Net Cash Flow From Investing Activities -44,037,000 12,518,000 22,664,000 -13,128,000
Net Cash Flow From Investing Activities, Continuing -44,037,000 12,518,000 22,664,000 -13,128,000
Net Cash Flow From Operating Activities 86,753,000 -25,555,000 -24,239,000 14,052,000
Net Cash Flow From Operating Activities, Continuing 86,753,000 -25,555,000 -24,239,000 14,052,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-16 2022-08-11 2022-11-10 2023-03-16
Comprehensive Income/Loss -37,512,000 -30,988,000 -30,919,000 -132,744,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -39,505,000 -31,780,000 -30,919,000 -132,744,000
Other Comprehensive Income/Loss 0 0 -30,919,000 -1,812,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-16 2022-08-11 2022-11-10 2023-03-16
Basic Earnings Per Share -1 -1 -1 -2
Benefits Costs and Expenses 38,555,000 32,366,000 32,948,000 136,040,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 38,555,000 32,366,000 32,948,000 136,040,000
Diluted Earnings Per Share -1 -1 -1 -2
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -37,512,000 -30,988,000 -30,749,000 -130,932,000
Income/Loss From Continuing Operations Before Tax -37,497,000 -30,970,000 -30,724,000 -130,841,000
Income Tax Expense/Benefit 16,000 18,000 25,000 91,000
Interest Expense, Operating 314,000 330,000 373,000 1,404,000
Net Income/Loss -37,513,000 -30,988,000 -30,749,000 -130,932,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -37,512,000 -30,988,000 -30,749,000 -130,932,000
Net Income/Loss Available To Common Stockholders, Basic -37,512,000 -30,988,000 -30,749,000 -130,932,000
Operating Expenses 38,494,000 32,747,000 33,962,000 139,030,000
Operating Income/Loss -37,436,000 -31,351,000 -31,738,000 -133,831,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 1,058,000 1,396,000 2,224,000 5,199,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2021-08-12 2021-11-10 2022-03-17
Assets UNPUB 495,630,000 469,725,000 437,375,000
Current Assets UNPUB 402,611,000 300,398,000 228,154,000
Current Liabilities UNPUB 21,225,000 19,868,000 15,655,000
Equity UNPUB 447,597,000 422,988,000 396,238,000
Equity Attributable To Noncontrolling Interest UNPUB 0 0 0
Equity Attributable To Parent UNPUB 447,597,000 422,988,000 396,238,000
Liabilities UNPUB 48,033,000 46,737,000 41,137,000
Liabilities And Equity UNPUB 495,630,000 469,725,000 437,375,000
Noncurrent Assets UNPUB 93,019,000 169,327,000 209,221,000
Noncurrent Liabilities UNPUB 0 26,869,000 25,482,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2021-08-12 2021-11-10 2022-03-17
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow UNPUB UNPUB -171,503,000 30,434,000
Net Cash Flow, Continuing UNPUB UNPUB -171,503,000 30,434,000
Net Cash Flow From Financing Activities UNPUB UNPUB -466,000 417,774,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB -466,000 417,774,000
Net Cash Flow From Investing Activities UNPUB UNPUB -147,054,000 -298,338,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB -147,054,000 -298,338,000
Net Cash Flow From Operating Activities UNPUB UNPUB -23,983,000 -89,002,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB -23,983,000 -89,002,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2021-08-12 2021-11-10 2022-03-17
Comprehensive Income/Loss UNPUB -23,273,000 -26,069,000 -96,471,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB -23,250,000 -26,069,000 -96,471,000
Other Comprehensive Income/Loss UNPUB 0 -26,069,000 -647,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2021-08-12 2021-11-10 2022-03-17
Basic Earnings Per Share UNPUB -2 0 -3
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB 0 -3
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB -23,273,000 -26,009,000 -95,824,000
Income/Loss From Continuing Operations Before Tax UNPUB -23,273,000 -26,009,000 -95,781,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 43,000
Interest Expense, Operating UNPUB 318,000 322,000 1,275,000
Net Income/Loss UNPUB -23,273,000 -26,009,000 -95,824,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Net Income/Loss Attributable To Parent UNPUB -23,273,000 -26,009,000 -95,824,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB -23,273,000 -26,009,000 -95,824,000
Operating Expenses UNPUB 23,021,000 25,827,000 94,883,000
Operating Income/Loss UNPUB -23,021,000 -25,827,000 -94,883,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB 0 0 0
Preferred Stock Dividends And Other Adjustments UNPUB 0 0 0
Revenues UNPUB 0 0 0
Calendar
15 May 2024 (Time UTC) Actual Previous Consensus
★
16:00
United States
MAR
100500000000.000
62900000000.000
★
16:00
United States
MAR
71500000000.000
89300000000.000
★
16:00
United States
MAR
102100000000.000
42000000000
★
16:00
United States
MAR
42200000000.000
87400000000.000
★★
15:20
United States
★
15:00
United States
MAR
★
15:00
United States
MAR
★★
12:00
United States
★
12:00
United States
★
11:00
United States
APR
0.300
0.400
★
10:30
United States
MAY 17
108000.000
-353000.000
★
10:30
United States
MAY 10
-45000.000
560000.000
770000.000
★
10:30
United States
MAY 10
-235000.000
915000.000
880000.000
★
10:30
United States
21000.000
275000.000
★
10:30
United States
MAY 10
307000.000
307000.000
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:IPSC240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:IPSC240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:IPSC240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:IPSC240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:IPSC240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:IPSC240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:IPSC240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:IPSC240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:IPSC240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:IPSC240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:IPSC240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:IPSC240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:IPSC240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:IPSC240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:IPSC240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:IPSC240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:IPSC240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:IPSC240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:IPSC240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:IPSC240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:IPSC240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:IPSC240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:IPSC240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:IPSC240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:IPSC231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:IPSC231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:IPSC231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:IPSC231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:IPSC231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:IPSC231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:IPSC231117P00007500 OPASPS Put American 100 7.5 BATO 2023-11-17
O:IPSC231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:IPSC231117P00002500 OPASPS Put American 100 2.5 BATO 2023-11-17
O:IPSC231117C00007500 OCASPS Call American 100 7.5 BATO 2023-11-17
O:IPSC231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:IPSC231117C00002500 OCASPS Call American 100 2.5 BATO 2023-11-17
O:IPSC231020P00007500 OPASPS Put American 100 7.5 BATO 2023-10-20
O:IPSC231020P00005000 OPASPS Put American 100 5 BATO 2023-10-20
O:IPSC231020P00002500 OPASPS Put American 100 2.5 BATO 2023-10-20
O:IPSC231020C00007500 OCASPS Call American 100 7.5 BATO 2023-10-20
O:IPSC231020C00005000 OCASPS Call American 100 5 BATO 2023-10-20
O:IPSC231020C00002500 OCASPS Call American 100 2.5 BATO 2023-10-20
O:IPSC230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:IPSC230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:IPSC230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:IPSC230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:IPSC230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:IPSC230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:IPSC230818P00007500 OPASPS Put American 100 7.5 BATO 2023-08-18
O:IPSC230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:IPSC230818P00002500 OPASPS Put American 100 2.5 BATO 2023-08-18
O:IPSC230818C00007500 OCASPS Call American 100 7.5 BATO 2023-08-18
O:IPSC230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:IPSC230818C00002500 OCASPS Call American 100 2.5 BATO 2023-08-18
News Stream
Calendar Calendar of Events
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
PHILADELPHIA, April 23, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a virtual fireside chat and panel at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, details of the presentations are as follows:
GlobeNewswire Inc. • 3w ago
News News
Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing
Thursday, Century Therapeutics (NASDAQ:IPSC) unveiled plans to expand clinical development for its lead program, CNTY-101, a CD19-targeting iNK cell therapy, into additional autoimmune disease indications.  CNTY-101 is currently being evaluated in a clinical trial in B-cell malignancies (ELiPSE-1) as well as a planned trial in systemic lupus erythematosus (SLE) (CALiPSO-1), which is on track to be initiated in the first half of 2024.  Century Therapeutics plans to pursue additional autoimmune disease indication regulatory filings in 2024.  The company announced a $60 million private placement to support Century Therapeutics’ increased R&D activities in autoimmune diseases.  Century will issue approximately 15.87 million shares at $3.78. The company estimates that its cash, cash equivalents, and investments will support operations into 2026. Concurrently, Century announced pipeline and ...Full story available on Benzinga.com
Benzinga • 1mo ago
Calendar Calendar of Events
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024. The posters highlight the Company’s end-to-end capabilities in iPSC reprogramming and differentiation, gene editing, synthetic biology, protein engineering and computational biology.
GlobeNewswire Inc. • 1mo ago
Calendar Calendar of Events
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a fireside chat a the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26th, 2024 at 1:30pm ET.
GlobeNewswire Inc. • 1mo ago
Stocks Earnings Releases and Operating Results
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
- Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that Allo-Evasion™ may support a multi-dosing regimen without the need for continued lymphodepletion -
GlobeNewswire Inc. • 2mo ago
News News
How Much Upside is Left in Century Therapeutics, Inc. (IPSC)? Wall Street Analysts Think 193.4%
The average of price targets set by Wall Street analysts indicates a potential upside of 193.4% in Century Therapeutics, Inc. (IPSC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Investment Research • 2mo ago
Calendar Calendar of Events
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Posters will highlight Century’s end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein engineering, Allo-Evasion™ technology and computational biology Posters will highlight Century’s end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein engineering, Allo-Evasion™ technology and computational biology
GlobeNewswire Inc. • 2mo ago
Calendar Calendar of Events
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Tuesday, February 8th, 2024 at 2:30 PM ET.
GlobeNewswire Inc. • 3mo ago
News Clinical Study
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
– Data presented at 65th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily pretreated R/R B-cell lymphoma patient –
GlobeNewswire Inc. • 5mo ago
News Conference Calls/ Webcasts
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
PHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that it will host a conference call and live audio webcast on Monday, December 11 at 7:30 AM PT/ 10:30 AM ET to discuss initial clinical data supporting a multi-dosing strategy from its ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101, the Company’s lead allogeneic, iPSC-derived CAR-iNK cell therapy, in relapsed/refractory CD19 positive B-cell lymphomas.
GlobeNewswire Inc. • 5mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT